New treatment approach for pulmonary hypertension: slowing harmful remodeling processes in the heart
DZL researchers have found that inhibiting a signaling pathway reduces pathological remodeling of the right ventricle in pulmonary hypertension.
DZL researchers have found that inhibiting a signaling pathway reduces pathological remodeling of the right ventricle in pulmonary hypertension.
In combination with single-cell technology, human tissue models will accelerate the translation of new antifibrotic agents in the future.
An imaging technique developed by DZL researchers can predict chronic rejection reactions that occur years after transplantation.
DZL scientist Prof. Dr. Silke Meiners investigates lung carcinomas. Her scientific findings show a link between cellular proteasome activity and a lack of response to immunotherapy in the treatment of lung cancer.
DZL scientists have studied the airways of patients with cystic fibrosis and analysed the genetic information of all microorganisms living there.
A clinical trial, conducted by an international team of DZL researchers has shown that a triple combination therapy consisting of three known compounds is both safe and effective in cystic fibrosis patients with relatively rare...
Professor Rajkumar Savai, MD, was awarded the Thoracic Oncology “Mid-Career Achievement Award” for his significant and meaningful contribution to thoracic oncology research at the 2023 Annual Meeting of the American Thoracic Society (ATS) International Conference...
An enzyme in alveoli cells protects most smokers from chronic obstructive pulmonary disease (COPD).
DZL researchers at Helmholtz Munich and their collaborators developed the Human Lung Cell Atlas using artificial intelligence (AI)-based techniques. This atlas elucidates the diversity of single lung cell types and allows learning about lung biology...
A team of researchers, with the participation of the DZL, discovered early epigenetic changes in the genome of COPD lung cells, which offer new insights into the disease's development and potential therapeutic options.
A Europe-wide project under the scientific leadership of DZL scientist Prof. Hans-Ulrich Kauczor aims to improve early lung cancer detection in all social groups.
This is what ideal medicine would look like: Doctors could specifically alter molecular processes in diseased cells in the body and thus cure patients causally.
